IMATINIB ZYDUS 400 mg, film-coated tablet scored 30 tablets
Active ingredients: Imatinib, Imatinib mesylate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet scored30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IMATINIB ZYDUS 400 mg, comprimé pelliculé sécable
- Pharmaceutical form
- comprimé pelliculé sécable
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC (ACLAR RX) polytrifluorochloroéthylène aluminium de 30 comprimé(s)
- Marketing authorisation holder
- ZYDUS FRANCE
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 27 Jun 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68931126CIP73024607CIP133400930246078Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IMATINIBcomprimé | 400,00 mg · un comprimé | FT |
| MÉSILATE D'IMATINIBcomprimé | 478,00 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.